Affymetrix last week launched its Axiom high-density genotyping arrays for genome-wide evaluation of microRNA target sites. The firm claimed that the new arrays will enable researchers to better understand how genomic variation in miRNA regulatory machinery influences gene expression and disease risk.
The catalog version of the array interrogates 238,000 SNPs and indels in genes for all parts of the miRNA cascade including miRNAs, their mRNA target sites, and silencing machinery, according to the firm. In addition to the catalog version, customers can choose to add their own content to the chips, including variants in long non-coding RNAs for disease association studies, Affy said. The catalog version is available immediately, while custom versions can be delivered within six weeks, the firm added.
Veredus Laboratories has launched VereMTB, a multiplexed molecular diagnostic chip capable of detecting of Mycobacterium tuberculosis complex and its mutations, as well as nine other clinically relevant non-tubercular mycobacterium. These mutations are responsible for resistance to multiple drugs and are reinvigorating the global spread of tuberculosis, according to the Singaporean firm.
VereMTB is based on STMicroelectronics' lab-on-chip technology and is currently undergoing evaluations by the Chinese Center for Disease Control and Prevention in Beijing as part of the center's ongoing program to assess new technologies for TB diagnostics, Veredus said.